Skip to content
lifestyle.timesla.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NEKTAR THERAPEUTICS
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2026
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026
Nektar Therapeutics Reports First Quarter 2026 Financial Results
May 24, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 23, 2026
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
May 22, 2026
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 22, 2026
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
May 21, 2026
Nektar Therapeutics Announces Proposed Public Offering
May 21, 2026
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
May 21, 2026
1
2
3
Next Page
→